One of the things I've learned over the last few years as an entrepreneur is that the Big Things that happen aren't what people think. Over the past few months, a few major changes have happened - both to PharmAla Biotech and the industry at large - that will absolutely transform the lives of patients seeking Psychedelic-Assisted Therapy in Canada. The first: Alberta Blue Cross announced a few weeks back that they were changing their policies to more closely align with, and support the funding of, Psychedelic-Assisted Therapy (PaT). This is the first time that a major third-party insurer has announced they are covering every element of PaT, from patient monitoring to drug to therapy cost. This change will drive insurance coverage in other places too - and PsyCan is working towards that goal. Over the next few weeks, we're also excited to announce the next step in PharmAla's work to expand MDMA access to more prescribers nationwide. Stay tuned!